← Back to Search

CAR T-cell Therapy

Loncastuximab Tesirine for Non-Hodgkin's Lymphoma

Phase 2
Recruiting
Led By Paolo Strati, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion and or average of 1 year
Awards & highlights

Study Summary

This trial will test if a new drug, loncastuximab tesirine, can help control large B-cell lymphoma that has returned or is resistant to CAR T-cell therapy. The safety and possible effects of the new drug will also be studied.

Who is the study for?
Adults with certain types of large B-cell lymphoma that didn't respond well to CAR T-cell therapy can join this trial. They should have partially responded to the previous treatment, be in good physical condition, and not have had any other cancer treatments since. People with heart issues, blood clots, severe allergies to study drugs, or active infections can't participate. Women who could get pregnant must test negative for pregnancy and agree to use birth control.Check my eligibility
What is being tested?
The trial is testing whether a drug called Loncastuximab Tesirine (lonca) can help control large B-cell lymphoma after CAR T-cell therapy has been given. It's for patients whose cancer hasn't fully responded and will look at how safe lonca is and what effects it might have.See study design
What are the potential side effects?
While the specific side effects of Loncastuximab Tesirine are not listed here, similar medications often cause symptoms like fatigue, allergic reactions during infusion into the body, liver problems, low blood cell counts increasing infection risk, and potential harm to an unborn baby.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion and or average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion and or average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of conversion to complete response

Trial Design

1Treatment groups
Experimental Treatment
Group I: Loncastuximab TesirineExperimental Treatment1 Intervention
Participants will receive Loncastuximab Tesirine (lonca) by vein.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Loncastuximab Tesirine
2022
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,975 Previous Clinical Trials
1,789,471 Total Patients Enrolled
Paolo Strati, MDPrincipal InvestigatorM.D. Anderson Cancer Center
3 Previous Clinical Trials
79 Total Patients Enrolled

Media Library

CAR T-cell Therapy (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05464719 — Phase 2
Non-Hodgkin's Lymphoma Research Study Groups: Loncastuximab Tesirine
Non-Hodgkin's Lymphoma Clinical Trial 2023: CAR T-cell Therapy Highlights & Side Effects. Trial Name: NCT05464719 — Phase 2
CAR T-cell Therapy (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05464719 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are some of the dangers associated with Loncastuximab Tesirine?

"While Phase 2 trials offer preliminary evidence regarding a medication's safety, there is no data yet supporting efficacy. Therefore, our team at Power has rated the Loncastuximab Tesirine as a 2."

Answered by AI

What is the total number of participants for this clinical trial?

"That is right, the clinicaltrials.gov website has information indicating that this study is looking for subjects. This research was originally put up on September 23rd, 2022 and was updated recently on the same day. The study needs 30 individuals from 1 location."

Answered by AI

Are there any available positions for participants in this trial?

"Yes, this study is looking for participants and the most recent update was on September 23rd, 2022."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
2022. "A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05464719.
~15 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top